Payment overview · 2025
General Payments
$246.57
7 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Lawrence Macmurray, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VISTA, CA · NPI 1386660280
Verified facts
What the public records show
CMS Open Payments records show Michael Lawrence Macmurray, M.D. received $246.57 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $121.63 | 49.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.36 | 16.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.50 | 12.4% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.12 | 9.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.69 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.27 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.57 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $121.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 153 |
| Losartan Potassium | Losartan Potassium | 407 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 72 |
| Naproxen | Naproxen | 249 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 50 |
| Metformin Hcl | Metformin Hcl | 183 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 44 |
| Lisinopril | Lisinopril | 169 | 54 |
| Trazodone Hcl | Trazodone Hcl | 150 | 30 |
| Gabapentin | Gabapentin | 148 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 34 |
| Famotidine | Famotidine | 102 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 27 |
| Glipizide | Glipizide | 89 | 25 |
| Carvedilol | Carvedilol | 87 | 24 |
| Alendronate Sodium | Alendronate Sodium | 86 | 24 |
| Furosemide | Furosemide | 79 | 26 |
| Meloxicam | Meloxicam | 77 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Omeprazole | Omeprazole | 60 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 18 |
| Baclofen | Baclofen | 50 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 14 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Lovastatin | Lovastatin | 42 | 12 |
| Simvastatin | Simvastatin | 42 | 16 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Eliquis | Apixaban | 27 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.57 · 7 records | Abbott Laboratories | APTIMA, CAPVAXIVE, CREON, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, LINZESS, ROTATEQ, Veozah, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error